Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry.

Alzheimer’s disease MAPT mutations Tau expression and purification frontotemporal dementia plasmid

Journal

ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337

Informations de publication

Date de publication:
07 10 2020
Historique:
pubmed: 25 8 2020
medline: 22 6 2021
entrez: 25 8 2020
Statut: ppublish

Résumé

Tau neurofibrillary tangles are key pathological features of Alzheimer's disease and other tauopathies. Recombinant protein technology is vital for studying the structure and function of tau in physiology and aggregation in pathophysiology. However, open-source and well-characterized plasmids for efficiently expressing and purifying different tau variants are lacking. We generated 44 sequence-verified plasmids including those encoding full length (FL) tau-441, its four-repeat microtubule-binding (K18) fragment, and their respective selected familial pathological variants (N279K, V337M, P301L, C291R, and S356T). Moreover, plasmids for expressing single (C291A), double (C291A/C322A), and triple (C291A/C322A/I260C) cysteine-modified variants were generated to study alterations in cysteine content and locations. Furthermore, protocols for producing representative tau forms were developed. We produced and characterized the aggregation behavior of the triple cysteine-modified tau-K18, often used in real-time cell internalization and aggregation studies because it can be fluorescently labeled on a cysteine outside the microtubule-binding core. Similar to the wild type (WT), triple cysteine-modified tau-K18 aggregated by progressive β-sheet enrichment, albeit at a slower rate. On prolonged incubation, cysteine-modified K18 formed paired helical filaments similar to those in Alzheimer's disease, sharing morphological phenotypes with WT tau-K18 filaments. Nonetheless, cysteine-modified tau-K18 filaments were significantly shorter (

Identifiants

pubmed: 32833429
doi: 10.1021/acschemneuro.0c00469
doi:

Substances chimiques

tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3117-3129

Auteurs

Thomas K Karikari (TK)

School of Life Sciences, University of Warwick, Coventry CV4 7AL, U.K.
Midlands Integrative Biosciences Training Partnership, University of Warwick, Coventry CV4 7AL, U.K.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg SE 43180, Sweden.

Sophie Keeling (S)

School of Life Sciences, University of Warwick, Coventry CV4 7AL, U.K.

Emily Hill (E)

School of Life Sciences, University of Warwick, Coventry CV4 7AL, U.K.

Juan Lantero Rodrı Guez (J)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg SE 43180, Sweden.

David A Nagel (DA)

School of Life and Health Sciences, Aston University, Birmingham B4 7ET, U.K.

Bruno Becker (B)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg SE 43180, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.

Kina Höglund (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg SE 43180, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg SE 43180, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1E 6BT, U.K.
UK Dementia Research Institute at UCL, London WC1E 6BT, U.K.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg SE 43180, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.

Eric J Hill (EJ)

School of Life and Health Sciences, Aston University, Birmingham B4 7ET, U.K.

Kevin G Moffat (KG)

School of Life Sciences, University of Warwick, Coventry CV4 7AL, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH